— Xlear, Inc., a global leader in creating natural, convenient, xylitol-based sinus and oral care products, announces today that the brand has partnered with The Institute for Antiviral Research (IAR) at Utah State University on a new study related to the potential impact of nasal spray on the SARS-CoV-2 (COVID-19) virus. Titled “Virucidal Activity of Xlear Compounds vs SARS-CoV-2 Virus and Rhinovirus-16” and released on May 21, 2020, the report found a potential link between the ingredients in the nasal spray and the deactivation of the virus. Xlear will continue to support research in this space, dedicated to eliminating and lowering the viral load in the upper airway, based on these preliminary findings.
Located on the campus of Utah State University, the Institute for Antiviral Research is comprised of a team of recognized scientists working to identify antiviral agents and vaccines against a wide range of human pathogenic viruses. Six principal investigators collaborate at the IAR with expertise in respiratory, hemorrhagic fever, and neuroinvasive viruses. Since being founded in 1978, the IAR and its researchers have been effectively involved in the pre-clinical development of several FDA-approved antiviral compounds in the past, including ribavirin (Virazole™), ganciclovir (Cytovene™), stavudine (Zerit™), and oseltamivir (Tamiflu™), as well as T-705 (favipiravir) which is approved for clinical use in Japan and being evaluated currently in the United States. Researchers at the IAR completed studies evaluating the in vitro and in vivo efficacy to support FDA approval.
The study combined Xlear nasal spray compound with virus stock at room temperature where the solution sat and reacted together for approximately 20 to 25 minutes. The solution was then neutralized with a formulated dilution prior to recording the results. Through the research and testing, the study reported seeing a decrease of the infectious virus after 20 minutes when the nasal spray ingredient was applied.
“With ninety percent of the viral load located in the upper airway, it is our belief that the most viable and cost effective solution will involve an antiviral via a nasal application, and, as a global leader in respiratory relief, supporting the medical community during this unprecedented time is of utmost importance to Xlear,” said Nathan Jones, CEO of Xlear. “We feel fortunate to be at the forefront of this research and will continue to partner with The Institute for Antiviral Research to further study the potential use of nasal spray in deactivation of the virus.”
“This study and the evidence provided is very promising and further research is needed to understand the next course of action,” said Dr. Lon Jones, D.O.. “As a brand devoted to natural sinus care we will continue to support research and movement towards finding a solution and until then we are proud to have a nasal spray on the market that has the potential to clear out the virus.”
Contact firstname.lastname@example.org to schedule an interview with Xlear Inc. CEO, Nathan Jones, or Dr. Lon Jones, DO regarding their research or to receive a copy of the study results. For more information on Xlear, Inc. and its brands, please visit www.xlear.com.
Founded in 2000, Xlear, Inc. is recognized as the leading manufacturer of natural, proactive health care products with xylitol. Xlear is committed to providing consumers with the highest quality products while striving to educate medical and dental professionals, as well their patients, about how using xylitol instead of sugar can help people live a much healthier and happy life. Xlear is supported by a team of doctors, hygienists and scientists who advocate the use and benefits of xylitol through continuous clinical research. Xlear, Inc. offers Xlear Nasal Spray, an award-winning, patented saline and xylitol nasal solution; a complete line of oral health products offered under the Spry Dental Defense System; and Lite&Sweet, a xylitol and erythritol sweetener used as a sugar substitute in cooking, baking and general consumption. For more information visit www.xlear.com.
Release ID: 88960873